本文選題：糖耐量減低 + 糖胰生2號�。� 參考：《山東中醫(yī)藥大學》2016年碩士論文

【摘要】：目的:通過臨床觀察及動物實驗研究兩個方面探討糖胰生2號方對糖耐量減低�；颊叩寞熜б约皩μ悄虿〈笫笱逡葝u素以及胰高血糖素樣肽1的影響。方法:1.臨床研究:將60例糖耐量減低患者隨機分為治療組和對照組,每組各30例,治療組:給予糖胰生2號聯(lián)合合理飲食及運動。對照組:合理飲食及運動。觀察兩組患者治療前后癥狀、血糖血脂、體重指數(shù)、胰島素抵抗指數(shù)等的變化情況。2.實驗研究:采用二聯(lián)造模方法(高糖高脂飼料+適量STZ腹腔注射)建立糖尿病大鼠模型,藥物干預6周后,采用酶聯(lián)免疫檢測方法觀察大鼠的血清胰島素以及胰高血糖素樣肽1的水平。結果:臨床結果:治療組中醫(yī)癥狀體征有所改善(P0.05),和對照組相比具有明顯的優(yōu)勢(P0.01);治療組FPG、2h PG及Hb A1c、TC、TG、LDL-C水平均顯著降低,組間比較有差異性(P0.05),HDL-C有所上升但組間無顯著差異;與對照組相比,治療組顯著降低BMI指數(shù)(P0.05)。實驗結果:與模型組相比較,中藥組以及二甲雙胍、西格列汀組均能降低體重及空腹血糖(P0.05),中藥高劑量組具有顯著優(yōu)勢(P0.01);西格列汀及中藥組分別與模型組相比較,在升高空腹胰島素方面具有明顯的優(yōu)勢(P0.01),且中藥組比二甲雙胍及西格列汀組更為有效(P0.05);與模型組相比,二甲雙胍、西格列汀組及中藥組胰島素抵抗指數(shù)顯著降低(P0.01),但中藥組與二甲雙胍組及西格列汀組相比無統(tǒng)計學意義(P0.05);與模型組相比二甲雙胍組及西格列汀組大鼠血清GLP-1水平有所上升,但是無統(tǒng)計學意義(P0.05),與模型組相比中藥組具有統(tǒng)計學差異(P0.05)。結論:糖胰生2號方能顯著改善臨床糖耐量減低患者的癥狀,降低血糖血脂,改善胰島素抵抗,并提高糖尿病大鼠血清胰島素以及胰高血糖素樣肽1的水平,保護糖尿病大鼠胰島β細胞的功能,刺激胰島β細胞的增殖和分化,抑制胰島β細胞的凋亡。
[Abstract]:Objective: to investigate the effect of Tang-Yisheng No. 2 recipe on patients with impaired glucose tolerance and on serum insulin and glucagon like peptide-1 in diabetic rats. Method 1: 1. Clinical study: 60 patients with impaired glucose tolerance were randomly divided into treatment group and control group with 30 cases in each group. Control group: reasonable diet and exercise. Observe the changes of symptoms, blood glucose, blood lipid, body mass index, insulin resistance index before and after treatment. Experimental study: the diabetic rat model was established by using the method of double modeling (high sugar and high fat diet with appropriate amount of STZ). After 6 weeks of drug intervention, the diabetic rat model was established. The levels of serum insulin and glucagon-like peptide 1 were measured by enzyme-linked immunosorbent assay (Elisa). Results: the symptoms and signs of traditional Chinese medicine in the treatment group were improved (P0.05), compared with the control group (P0.01), the levels of 2h PG and HbA1cTCU TGN LDL-C in the treatment group were significantly lower than those in the control group (P0.05), but there was no significant difference between the treatment group and the control group (P0.05). Compared with the control group, the treatment group significantly decreased BMI (P0.05). Results: compared with the model group, the traditional Chinese medicine group and metformin and ciglutin groups could reduce body weight and fasting blood glucose (P0.05), the high dose group had significant advantage (P0.01), the ciglutin group and the traditional Chinese medicine group were compared with the model group. It has obvious advantage in increasing fasting insulin (P0.01), and the Chinese medicine group is more effective than metformin group and siglitatin group (P0.05), compared with the model group, metformin group, The insulin resistance index of ciglutin group and traditional Chinese medicine group decreased significantly (P0.01), but there was no significant difference between Chinese medicine group and metformin group and siglitatin group (P0.05), and the serum GLP-1 level of metformin group and siglitatin group was higher than that of model group. But there was no statistical significance (P0.05), compared with the model group, the traditional Chinese medicine group had statistical difference (P0.05). Conclusion: Tang Yisheng 2 prescription can significantly improve the symptoms of patients with impaired glucose tolerance, reduce blood glucose, blood lipid, improve insulin resistance, and increase the levels of serum insulin and glucagon like peptide 1 in diabetic rats. To protect the function of islet 尾 cells, stimulate the proliferation and differentiation of islet 尾 cells and inhibit the apoptosis of islet 尾 cells in diabetic rats.
【學位授予單位】：山東中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R259

【引證文獻】

相關碩士學位論文 前1條

1 李志鵬;地香知珠消渴方對2型糖尿病大鼠的影響及作用機制的初步研究[D];云南中醫(yī)學院;2017年

，

本文編號：2085871